Free Trial

ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

$11.35
+0.24 (+2.16%)
(As of 07/12/2024 ET)

ARS Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$18.50
63.00% Upside
High Forecast$19.00
Average Forecast$18.50
Low Forecast$18.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.50$18.50$18.50$13.67
Forecasted Upside63.00% Upside115.24% Upside115.24% Upside86.45% Upside
Get ARS Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.

SPRY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SPRY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ARS Pharmaceuticals Stock vs. The Competition

TypeARS PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside63.00% Upside991.28% Upside9.19% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/11/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$19.00+122.48%
3/5/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Ruiz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/5/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$6.00 ➝ $18.00+108.09%
2/20/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:57 PM ET.

SPRY Forecast - Frequently Asked Questions

What is ARS Pharmaceuticals' forecast for 2024?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for ARS Pharmaceuticals is $18.50, with a high forecast of $19.00 and a low forecast of $18.00.

Should I buy or sell ARS Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRY shares.

Does ARS Pharmaceuticals's stock price have much upside?

According to analysts, ARS Pharmaceuticals's stock has a predicted upside of 115.24% based on their 12-month stock forecasts.

Do Wall Street analysts like ARS Pharmaceuticals more than its competitors?

Analysts like ARS Pharmaceuticals more than other "medical" companies. The consensus rating for ARS Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SPRY compares to other companies.


This page (NASDAQ:SPRY) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners